Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 17, 2018. The document serves as a transaction notification regarding a specific corporate action involving the company's American Depositary Shares (ADSs).
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports solely on a specific securities transaction:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Type: Acquisition of ADSs via dividend reinvestment.
- Transaction Date: July 12, 2018.
- Transaction Price: $41.75 per ADS.
- Total Volume: 394.792 ADSs.
- Exchange: New York Stock Exchange (XYNS).
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It documents a routine administrative transaction where dividends paid to shareholders on July 12, 2018, were reinvested into ADSs held in the Company's US Deferred Performance Share Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or discussion of contingencies. The document is strictly a regulatory notification of a transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a closely associated person.
Key Facts for Investor Verification
- Verify the impact of the dividend reinvestment on the total share count of the US Deferred Performance Share Plan.
- Confirm the identity of the PDMR involved: Mr. D E Troy, SVP & General Counsel.
- Note that this filing does not reflect the company's broader financial performance for the quarter or year.